Vaxart, Inc.
VXRT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.27 | 0.15 | -0.08 | -0.39 |
| FCF Yield | -14.05% | -25.91% | -22.31% | -2.13% |
| EV / EBITDA | -5.84 | -3.76 | -4.49 | -44.18 |
| Quality | ||||
| ROIC | -80.21% | -98.50% | -82.88% | -34.28% |
| Gross Margin | 100.00% | 39.02% | 100.00% | -5,365.13% |
| Cash Conversion Ratio | 0.67 | 0.85 | 0.88 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 544.91% | 102.24% | -70.21% | 962,520.16% |
| Free Cash Flow Growth | 37.34% | 30.71% | -60.61% | -160.24% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | 0.11 | 0.16 | 1.79 |
| Interest Coverage | -22.33 | -57.60 | -87.81 | -49.16 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 152.22 | 20.31 | 68.22 | 0.06 |